Eylea biosimilars comparison
BiosimilarsCompare aflibercept biosimilars to brand Eylea for wet AMD and DME. Several biosimilars have been FDA-approved, offering potential cost savings for retinal anti-VEGF therapy.
Select any two to compare side by side
All products in this comparison
| Product | Manufacturer | Route | Frequency | Key difference |
|---|---|---|---|---|
| Eylea (reference) | Regeneron | Intravitreal injection | Every 4–8 weeks | Original reference product; extensive retinal disease data |
| Yesafili (aflibercept-jbvf) | Samsung Bioepis | Intravitreal injection | Every 4–8 weeks | FDA-approved aflibercept biosimilar |
| Byooviz (ranibizumab-nuna) | Samsung Bioepis | Intravitreal injection | Monthly | Ranibizumab (Lucentis) biosimilar: alternative anti-VEGF option |
| Cimerli (ranibizumab-eqrn) | Coherus | Intravitreal injection | Monthly | Ranibizumab biosimilar; interchangeable |
Related guides
Denied one of these medications?
Ellen can decode your denial letter, identify why you were denied, and generate a personalized appeal, free for patients.